X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreements, Glenmark will receive from Cassiopea, the exclusive right to commercialize Winlevi (clascoterone cream), used on the skin (topical) to treat acne vulgaris in people 12 years of age and older, in 15 EU countries as well as in South Africa and the UK.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Licensing Agreement September 27, 2023
Details:
Under the terms of the above referred agreements, Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI (clascoterone) in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $7.0 million
Deal Type: Licensing Agreement July 25, 2022
Details:
Results from two pivotal clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne)showed favorable safety and efficacy data for WINLEVI in patients with acne aged 12 years and older.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sun Pharmaceutical Industries Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi® in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $235.0 million Upfront Cash: $45.0 million
Deal Type: Licensing Agreement July 26, 2021
Details:
Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Curia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
Winlevi (clascoterone cream 1%) is approved for the treatment of acne vulgaris in people aged 12 and older. In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The study demonstrated that Clascoterone cream 1%, has favorable long-term safety for the treatment of acne with low rates of treatment related adverse events (AEs).
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: CB-03-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
